Search Results
Your search for Matthew Stenger ,Matthew Stenger matches 7475 pages
Showing 2801 - 2850First-Line FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for Localized Pancreatic Cancer
In a single-institution retrospective study reported in JAMA Surgery, Perri et al found that first-line FOLFIRINOX (fluorouracil, leucovorin, irinotecan, and oxaliplatin) was associated with a higher response rate and subsequent pancreatectomy vs gemcitabine plus nab-paclitaxel in patients with...
Outcomes With Axicabtagene Ciloleucel in the Nontrial Setting in Patients With B-Cell Non-Hodgkin Lymphoma
In a study reported in the Journal of Clinical Oncology, Caron A. Jacobson, MD, and colleagues found that commercial use of the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel in patients with relapsed or refractory B-cell non-Hodgkin lymphoma was associated with an overall...
Effect of Breast Cancer Pathway Implementation on Rate of Referrals for Genetic Counseling and Testing
In a study reported in JCO Oncology Practice, Stephanie L. Graff, MD, and colleagues found that patients with breast cancer seen by a physician with training in using an established pathway for genetic counseling and testing referral were more frequently referred for such services vs patients seen...
Addition of Antithymocyte Globulin to Graft-vs-Host Disease Prophylaxis in Matched Sibling Donor Stem Cell Transplant
In a Chinese trial reported in the Journal of Clinical Oncology, Chang et al found that the addition of antithymocyte globulin to standard graft-vs-host disease prophylaxis reduced the risk of acute graft-vs-host disease in patients undergoing human leukocyte antigen (HLA)-matched sibling donor...
Collaborative Guideline for the Diagnosis and Management of Lung Neuroendocrine Tumors
As reported in the Journal of Thoracic Oncology by Simron Singh, MD, MPH, and colleagues, the Commonwealth Neuroendocrine Tumour Research Collaboration (CommNETs) and North American Neuroendocrine Tumor Society (NANETS) have collaborated to produce a best practice guideline for the diagnosis and...
Avapritinib in Advanced PDGFRA D842V–Mutant Gastrointestinal Stromal Tumors
As reported in The Lancet Oncology by Heinrich et al, the phase I NAVIGATOR trial showed that the PDGFRA and KIT kinase inhibitor avapritinib produced a response in patients with PDGFRA D842V–mutant gastrointestinal stromal tumors (GIST). The study supported the January 2020 approval of...
Adjuvant Chemotherapy vs Active Surveillance: Survival After Resection of Isolated Synchronous Colorectal Peritoneal Metastases
In a Dutch population-based observational cohort study reported in JAMA Oncology, Rovers et al found that adjuvant systemic chemotherapy was associated with improved overall survival vs active surveillance after upfront resection of isolated synchronous colorectal peritoneal metastases. Study...
Margetuximab/Pembrolizumab for Previously Treated Patients With HER2-Positive Advanced Gastroesophageal Adenocarcinoma
In a phase Ib/II trial reported in The Lancet Oncology, Daniel V.T. Catenacci, MD, and colleagues found that the combination of margetuximab and the anti–PD-1 therapy pembrolizumab showed evidence of activity in patients with previously treated HER2-positive gastroesophageal adenocarcinoma. As...
Long-Term Normal Tissue Effects With Five-Fraction Whole-Breast Radiotherapy for Early Breast Cancer
As reported in the Journal of Clinical Oncology by Brunt et al, 10-year follow-up in the FAST trial of women with early breast cancer showed greater risk for photographic- and physician-assessed normal tissue effects with an adjuvant radiotherapy regimen of 30 Gy in 5 once-weekly fractions—but not...
Longitudinal Analysis of Health-Related Quality of Life in Patients With Hodgkin Lymphoma
A longitudinal analysis of health-related quality of life in patients from German Hodgkin Study Group trials, reported in the Journal of Clinical Oncology by Kreissl et al, showed a “high and persistent” amount of health-related quality-of-life deficits in survivors of Hodgkin lymphoma. The...
Pembrolizumab for Advanced Melanoma: Impact of BRAF-Mutation Status and Prior Therapeutic Regimens
In a pooled analysis reported in JAMA Oncology, Igor Puzanov, MD, MSCI, and colleagues identified objective response rates and progression-free and overall survival rates with pembrolizumab treatment among patients with advanced melanoma according to BRAF V600E/K–mutation status and prior BRAF/MEK...
Phase Ib Trial of Atezolizumab With or Without Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
The combination of atezolizumab and bevacizumab was recently approved by the U.S. Food and Drug Administration for the treatment of unresectable or metastatic hepatocellular carcinoma on the basis of findings from the phase III IMbrave150 trial, which showed superior overall and progression-free...
LACC Trial: Quality of Life With Open vs Minimally Invasive Radical Hysterectomy for Patients With Cervical Cancer
As reported in The Lancet Oncology by Frumovitz et al, there were no significant differences in quality of life, a secondary endpoint, for women undergoing open vs minimally invasive radical hysterectomy for cervical cancer in the phase III LACC trial. There were, however, differences in...
Effect of Complete vs Incomplete Macroscopic Excision on Survival in Stage IV High-Risk Neuroblastoma
In an analysis from the International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN) High-Risk Neuroblastoma 1 (HR-NBL1/SIOPEN) trial reported in the Journal of Clinical Oncology, Holmes et al found that surgeon-assessed complete macroscopic excision was associated with improved...
Quality of Life With Timing of Platinum-Based Regimens in Newly Diagnosed Patients With Ovarian Cancer
In a study reported in The Lancet Oncology, Blagden et al found lower mean global quality-of-life scores on longitudinal analysis among women with newly diagnosed ovarian cancer who received weekly vs every-3-week paclitaxel in platinum-based regimens in the ICON8 trial. The ICON8 trial showed no...
Effectiveness of Routine Blood Testing in Detection of Disease During Active Surveillance for Indolent Non-Hodgkin Lymphoma
In an Australian study reported in JCO Oncology Practice, Piercey et al found that routine blood tests have little utility in detecting relapse or progression of disease during active surveillance of patients with indolent non-Hodgkin lymphoma. As stated by the investigators, “Patients with...
Outcomes According to BMI in Women Receiving Adjuvant Docetaxel-Based Chemotherapy for Early Breast Cancer
A retrospective analysis from the BIG 2-98 trial reported in the Journal of Clinical Oncology by Desmedt et al showed poorer disease-free and overall survival with increasing baseline body mass index (BMI) in women receiving adjuvant docetaxel-based chemotherapy but not among those receiving...
Teriparatide for Medication-Related Osteonecrosis of the Jaw
In an Australian study reported in the Journal of Clinical Oncology, Sim et al found that the osteoanabolic agent teriparatide improved the rate of resolution of medication-related osteonecrosis of the jaw lesions vs placebo in a population of patients who had previous exposure to either...
Effects of Exercise Intolerance on Adult Survivors of Childhood Cancer
In a study reported in JAMA Oncology, Hayek et al found that exercise intolerance was more common among adult survivors of childhood cancer than among matched controls and that it was associated with a greater likelihood of emotional distress, poorer attainment of social roles, and poorer...
Liver Transplantation After Tumor Downstaging in Patients With Hepatocellular Carcinoma
In an Italian phase IIb/III study reported in The Lancet Oncology, Mazzaferro et al found evidence that liver transplantation after tumor downstaging was associated with improved event-free and overall survival in patients with hepatocellular carcinoma. The study was closed early due to changes in...
Dental Infection Screening Before Induction Chemotherapy for AML
In a single-institution study reported in JCO Oncology Practice, Watson et al found that screening for and treating detected dental infections prior to initiation of induction chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) were associated with a significant reduction in ...
Effect of Medicaid Expansion on Breast Cancer Stage at Diagnosis
In a study reported in JAMA Surgery, Le Blanc et al found that Medicaid expansion under the Affordable Care Act was associated with increased insurance coverage and reduction in rates of diagnosis of breast cancer at later stages. Study Details The study involved data from the National Cancer...
Potential Association of Impaired Spermatogenesis and Immune Checkpoint Inhibitor Therapy in Patients With Metastatic Melanoma
In a study reported as a research letter in JAMA Oncology, Scovell et al identified a potential association between the use of immune checkpoint inhibitors and impaired spermatogenesis using autopsy tissue findings in men with a history of metastatic melanoma. Study Details The study involved...
Addition of Capecitabine to T-DM1 in Previously Treated Patients With HER2-Positive Metastatic Breast Cancer
In the phase I/II TRAXHER2 trial reported in JAMA Oncology, Cortés et al found that the combination of capecitabine and ado-trastuzumab emtansine (T-DM1) did not improve overall response rate vs T-DM1 alone in previously treated patients with HER2-positive metastatic breast cancer. Study Details In ...
Cabozantinib in Platinum-Refractory Metastatic Urothelial Carcinoma
In a single-center phase II trial reported in The Lancet Oncology, Andrea Apolo, MD, and colleagues found that the multikinase inhibitor cabozantinib showed activity in a cohort of patients with platinum-refractory metastatic urothelial carcinoma. As noted by the investigators, in addition to...
Atezolizumab as First-Line Treatment of Metastatic NSCLC With High PD-L1 Expression and No EGFR or ALK Aberrations
On May 18, 2020, atezolizumab was approved for the first-line treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression and no EGFR or ALK genomic tumor aberrations. High PD-L1 expression is defined as PD-L1 staining of at least 50% of...
Prolonged Overall Survival With Autologous-Allogeneic vs Tandem Autologous Transplant in Newly Diagnosed Myeloma
In a pooled analysis reported in Bone Marrow Transplantation,1 Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham, and colleagues found that autologous hematopoietic cell transplantation followed by reduced-intensity conditioning allogeneic transplantation (auto-allo) was...
Atezolizumab Plus Bevacizumab for Unresectable or Metastatic Hepatocellular Carcinoma
On May 29, 2020, atezolizumab in combination with bevacizumab was approved for treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.1-3 Supporting Efficacy Data Approval was based on findings in the international, open-label,...
Rucaparib in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
On May 15, 2020, rucaparib was granted accelerated approval for the treatment of patients with deleterious BRCA mutation–associated (germline or somatic) metastatic castration-resistant prostate cancer who have been treated with androgen receptor–directed therapy and taxane-based chemotherapy.1,2...
IMbrave150 Trial: Atezolizumab Plus Bevacizumab Improves Survival in Unresectable Hepatocellular Carcinoma
As reported in The New England Journal of Medicine by Richard S. Finn, MD, of Jonsson Comprehensive Cancer Center, Geffen School of Medicine at the University of California, Los Angeles, and colleagues, the phase III IMbrave150 trial has shown that anti–programmed cell death ligand 1 (PD-L1) plus...
Nivolumab Plus Ipilimumab in Two New Lung Cancer Indications
The combination of nivolumab and ipilimumab was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with non–small cell lung cancer (NSCLC) in two different regimens: On May 15, 2020, the two-drug combination was approved for first-line treatment in...
Daratumumab and Hyaluronidase-fihj for Multiple Myeloma
On May 1, 2020, the combination of daratumumab and hyaluronidase-fihj was approved for adult patients with newly diagnosed or relapsed/refractory multiple myeloma. This new product allows for subcutaneous (SC) dosing of daratumumab.1,2 Daratumumab and hyaluronidase-fihj is for SC use only. The...
Event-Free Survival as a Surrogate for Overall Survival in Patients With Localized Prostate Cancer Treated With Radiotherapy
In a study reported in the Journal of Clinical Oncology, Xie et al found that event-free survival including prostate-specific antigen biochemical failure as an event is not an adequate surrogate for overall survival in men receiving radiotherapy as primary therapy for localized prostate cancer....
GI-Related Patient-Reported Outcomes in Individuals Receiving Chemoradiation for Anal Cancer
In a single-institution study reported in JCO Oncology Practice, Kouzy et al found that gastrointestinal (GI)-related patient-reported outcomes among those receiving chemoradiation for anal cancer improved vs baseline at 1 week after treatment initiation, were worse vs baseline at 5 weeks, but did...
Survival With Different Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplant in Patients With Non-Hodgkin Lymphoma
In a study reported in JAMA Oncology, Ghosh et al found that a more intense reduced-intensity conditioning and nonmyeloablative conditioning (RIC-NMAC) regimen consisting of fludarabine plus melphalan at 140 mg/kg (Flu-Mel14) appears to be associated with poorer overall survival and higher...
Post Hoc Analysis of Outcomes With Vandetanib for Progressive and Symptomatic Medullary Thyroid Cancer
As reported in the Journal of Clinical Oncology by Kreissl et al, a post hoc analysis of outcomes in the pivotal phase III ZETA trial has shown significantly improved progression-free survival with the multikinase inhibitor vandetanib vs placebo in a subgroup of patients with progressive and...
Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
In the phase IIb SADAL trial reported in The Lancet Haematology, Kalakonda et al found that the oral nuclear export inhibitor selinexor produced durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma. Findings in the trial supported the recent accelerated U.S. Food...
Phase I Trial of Berzosertib Alone or Combined With Carboplatin in Advanced Solid Tumors
In a phase I trial reported in the Journal of Clinical Oncology, Timothy A. Yap, MBBS, PhD, FRCP, and colleagues identified recommended phase II doses of the first-in-class ATR (ataxia telangiectasia and Rad3–related) kinase inhibitor berzosertib alone and in combination with carboplatin and found...
Lenvatinib Plus Pembrolizumab for Advanced Gastric Cancer
In the Japanese single-center phase II EPOC1706 trial reported in The Lancet Oncology, Kawazoe et al found high objective response among patients with advanced gastric cancer who received the combination of lenvatinib and pembrolizumab as first- or second-line treatment. Study Details The trial...
Adding Cyclophosphamide to Bortezomib/Dexamethasone in Patients With Multiple Myeloma and Acute Kidney Injury From Cast Nephropathy
In a French trial reported in the Journal of Clinical Oncology, Bridoux et al found adding cyclophosphamide to bortezomib/dexamethasone offered no benefit for renal recovery of patients with multiple myeloma and initial cast nephropathy not requiring dialysis. Study Details In the multicenter...
Patient Factors Associated With Lack of Provider Recommendation for HPV Vaccination in Young Cancer Survivors
In a study reported in the Journal of Clinical Oncology, York et al found that perceived lack of insurance coverage for human papillomavirus (HPV) vaccine, male sex, and decreased parent-survivor communication regarding HPV vaccination were among the factors associated with an increased likelihood...
Phase I Trial of Berzosertib Alone or Combined With Carboplatin in Advanced Solid Tumors
In a phase I trial reported in the Journal of Clinical Oncology, Timothy A. Yap, MBBS, PhD, FRCP, and colleagues identified recommended phase II doses of the first-in-class ATR (ataxia telangiectasia and Rad3–related) kinase inhibitor berzosertib alone and in combination with carboplatin and found...
Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
In the phase IIb SADAL trial reported in The Lancet Haematology, Kalakonda et al found that the oral nuclear export inhibitor selinexor produced durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma. Findings in the trial supported the recent accelerated U.S. Food...
Lenvatinib Plus Pembrolizumab for Advanced Gastric Cancer
In the Japanese single-center phase II EPOC1706 trial reported in The Lancet Oncology, Kawazoe et al found high objective response among patients with advanced gastric cancer who received the combination of lenvatinib and pembrolizumab as first- or second-line treatment. Study Details The trial...
Risk of Breast Cancer Recurrence: Serum Detection of Nonadherence to Adjuvant Tamoxifen
In a French study reported in the Journal of Clinical Oncology, Pistilli et al found that serum detection of nonadherence to adjuvant tamoxifen therapy was common and was associated with poorer distant disease-free survival among premenopausal women with breast cancer. Biochemical nonadherence was...
Ursodeoxycholic Acid for Preventing Gallstones After Gastrectomy for Gastric Cancer
In a Korean trial reported in JAMA Surgery, Lee et al found that treatment with ursodeoxycholic acid was successful in preventing gallstone formation in patients who had undergone gastrectomy for gastric cancer. Study Details In the multicenter double-blind trial, 465 evaluable patients undergoing...
Addition of an ATR Inhibitor to Gemcitabine in Platinum-Resistant High-Grade Serous Ovarian Cancer
As reported in The Lancet Oncology by Panagiotis A. Konstantinopoulos, MD, and colleagues, a phase II trial has shown significantly prolonged progression-free survival with the addition of the ATR (ataxia telangiectasia and Rad3–related) kinase inhibitor berzosertib to gemcitabine in women with...
Meta-analysis of Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer
In a systematic review and meta-analysis of observational studies reported in JAMA Oncology, Nitecki et al found that minimally invasive radical hysterectomy was associated with increased risk of recurrence and all-cause mortality vs open surgery in women with early-stage cervical cancer. Study...
Addition of First-Line Atezolizumab to Vemurafenib and Cobimetinib in Patients With Unresectable Advanced BRAF V600–Mutant Melanoma
As reported in The Lancet by Gutzmer et al, the phase III IMspire150 trial has shown that the addition of atezolizumab to BRAF and MEK inhibitor therapy with vemurafenib and cobimetinib improved progression-free survival in first-line treatment of patients with unresectable BRAF V600–mutant...
Mortality Risk in Patients With COVID-19 and Thoracic Malignancies: Initial Report From the TERAVOLT Registry Study
As reported in The Lancet Oncology by Marina C. Garassino, MD, and colleagues, initial findings from the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry study have identified potential factors associated with increased risk of mortality in patients infected with COVID-19...
